We can't find the internet
Attempting to reconnect
Something went wrong!
Hang in there while we get back on track
Artificial intelligence-powered new approach methodologies for assessing combined toxicity of chemical mixtures
Summary
In real life, we're never exposed to just one chemical at a time — we're surrounded by mixtures like microplastics carrying antibiotics and heavy metals, which can interact in ways that are harder to predict and study than single toxins. This review looks at how new AI tools could help scientists better predict how these chemical combinations affect our health, potentially catching dangerous interactions that older, one-chemical-at-a-time testing methods miss. It's not a new experiment, but rather a roadmap summarizing how AI could improve chemical safety testing, while stressing that these tools still need rigorous validation before regulators can fully trust their pred
Chemical contaminants in the environment invariably occur as complex mixtures, yet conventional risk assessment paradigms rely on single‑chemical evaluations that cannot capture emergent synergistic or antagonistic interactions. This review critically examines how artificial intelligence (AI) integrated with New Approach Methodologies (NAMs) is fundamentally reshaping mixture toxicity assessment. We directly compare four AI architectures traditional machine learning, Graph Neural Networks (GNNs), SMILES‑based Transformers, and the highly interpretable q‑RASAR framework, critically evaluating their respective abilities to model non‑additive mixture effects, handle data scarcity, and meet regulatory interpretability standards. We address critical blind spots in emerging contaminant mixtures, including microplastics acting as vectors for antibiotics and heavy metals, and nanomaterial‑driven acceleration of antibiotic resistance gene transfer. A central theme is the indispensable transition from statistical correlation to causal biological proof: we delineate the boundary between statistical explainability (SHAP values) and mechanistic explainability (Adverse Outcome Pathways), and we propose a closed‑loop validation strategy that combines in vitro organoid assays, AOP mapping, and AI‑optimized PBPK modeling. Finally, we provide a regulatory roadmap that emphasizes globally standardized validation protocols (e.g., the OECD (Q)SAR Assessment Framework), large‑scale chemistry‑biology interaction databases for zero‑shot mixture predictions, Bayesian uncertainty quantification, and legal frameworks for liability when using black‑box models.